Patent ID: 11897927
Assignee: ADVAXIS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 41:
42. The recombinant Listeria strain of claim 41, wherein:
(a) the antigenic peptides comprise one or more or all of the following recurrent cancer mutations: KRAS\_G12C, EGFR_L858R, KRAS\_G12D, U2AF1_S34F, BRAF_V600E, KRAS\_G12V, PIK3CA_E545K, TP53_R158L, KRAS\_G12A, EGFR_L861Q, and TP53_R273L;
(b) the antigenic peptides comprise one or more or all of the following recurrent cancer mutations: SPOP_F133V, CHEK2_K373E, RGPD8_P1760A, ANKRD36C_I634T, ANKRD36C_D629Y, SPOP_W131G, ANKRD36C_D626N, SPOP_F133L, AR_T878A, AR_L702H, AR_W742C, AR_H875Y, and AR_F877L;
(c) the antigenic peptides comprise one or more or all of the following recurrent cancer mutations: KRAS\_G12C, KRAS\_G12D, U2AF1_S34F, KRAS\_G12V, TP53_R248Q, TP53_R248W, TP53_R175H, TP53_R273C, KRAS\_G12R, KRAS\_Q61H, TP53_R282W, TP53_R273H, TP53_G245S, SMAD4_R361C, GNAS_R201C, and GNAS_R201H;
(d) the antigenic peptides comprise one or more or all of the following recurrent cancer mutations: PIK3CA_E545K, FGFR3_S249C, TP53_R248Q, PIK3CA_E542K, RXRA_S427F, FBXW7_R505G, TP53_R280T, NFE2L2_E79K, FGFR3_R248C, TP53_K132N, TP53_R248W, TP53_R175H, and TP53_R273C;
(e) the antigenic peptides comprise one or more or all of the following recurrent cancer mutations: PIK3CA_E545K, PIK3CA_E542K, PIK3CA_H1047R, AKT1_E17K, PIK3CA_H1047L, PIK3CA_Q546K, PIK3CA_E545A, PIK3CA_E545G, ESR1_K303R, ESR1_D538G, ESR1_Y537S, ESR1_Y537N, ESR1_Y537C, and ESR1_E380Q;
(f) the antigenic peptides comprise one or more or all of the following recurrent cancer mutations: PTEN_R130G, PTEN_R130Q, KRAS\_G12D, KRAS\_G12V, PIK3CA_H1047R; PIK3CA\R88Q, PIK3CA_E545K, PIK3CA_E542K, CTNNB1_S37F, KRAS\_G13D, CTNNB1_S37C, PIK3CA_H1047L, PIK3CA_G118D, KRAS\_G12A, FBXW7_R505C, and TP53_R248W;
(g) the antigenic peptides comprise one or more or all of the following recurrent cancer mutations: TP53_R248Q, TP53_R248W, TP53_R175H, TP53_R273C, TP53_R282W, TP53_R273H, TP53_Y220C, TP53_1195T, TP53_C176Y, TP53_H179R, TP53_S241F, and TP53_H193R;
(h) the antigenic peptides comprise one or more or all of the following recurrent cancer mutations: TP53_R273L, TP53_R273C, TP53_R273H, PIK3CA_G118D, IDH1_R132C, IDH1_R132G, IDH1_R132H, IDH1_R132S, IDH2_R172K, PIK3CA_E453K, and EGFR\G598V;
(i) the antigenic peptides comprise one or more or all of the following recurrent cancer mutations: KRAS\_G12C, KRAS\_G12D, BRAF_V600E, KRAS\_G12V, PIK3CA_E545K, TP53_R248W, TP53_R175H, TP53_R273C, PIK3CA_H1047R, TP53_R282W, TP53_R273H, and KRAS\_G13D; or
(j) the antigenic peptides comprise one or more or all of the following recurrent cancer mutations: PIK3CA_E545K, CHEK2_K373E, RGPD8_P1760A, ANKRD36C_I634T, TP53 R248Q, PIK3CA_E542K, TP53_R248W, TP53_R175H, PIK3CA_H1047R, TP53_R282W, TP53_R273H, TP53_G245S, TP53_Y220C, ZNF814_D404E, KRTAP1-5_I88T, KRTAP4-11_L161V, and HRAS_G13V.